Annual General Meeting Statement
22/06/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230622:nRSV5141Da&default-theme=true
RNS Number : 5141D Ergomed plc 22 June 2023
PRESS RELEASE
Annual General Meeting Statement
Guildford, UK - 22 June 2023: Ergomed plc (LSE: ERGO) ('Ergomed' or the
'Company'), a company focused on providing specialised services to the
pharmaceutical industry, announces the following update from Dr Miroslav
Reljanović, Executive Chairman, in advance of the Company's Annual General
Meeting ('AGM') to be held this morning at 9.30am BST:
"Ergomed started the year from a position of strength, having finished 2022
with a strong order book. The Company has made a good start to the year, with
solid overall growth in revenues reflecting our resilient services-based
business model and the global strength of our offering.
The Company has continued to invest in its commercial expansion,
infrastructure, and platform to support sustainable future growth while
continuing to ensure prudent cost management. Investment has primarily been in
our North American commercial capabilities, our global senior leadership
presence, and also in technology as we continue to enhance our digital
capabilities and the expansion of our service offering to our client base.
Simultaneously, we continue our disciplined approach to strategic M&A,
actively seeking and assessing potential acquisitions which would complement
our existing business and strengthen our global footprint.
The Company remains in a robust financial position, debt free, with a strong
balance sheet and unutilised facilities of up to £80.0 million to support
continued expansion both organically and through acquisitions.
Ergomed continues to demonstrate its resilience and increasing competitive
strength, notwithstanding the continued macro-economic challenges. Based on
our trading performance since the start of the year, the Board anticipates
financial results for the full year 2023 to be in line with market
expectations.
In line with previous practice, we will provide more detail on trading during
the first half of 2023 and the outlook for the 2023 financial year in the
Company's July Trading Update.
On behalf of the Board, I would like to thank all the Company's staff and
shareholders for their continuing support, and we look forward to the rest of
this year and beyond with confidence and enthusiasm."
ENDS
Enquiries:
Ergomed plc
Miroslav Reljanović (Executive Chairman)
Jonathan Curtain (Chief Financial Officer)
Keith Byrne (Senior Vice President, Capital Markets and Strategy)
Tel: +44 (0) 1483 402 975
Numis (Nominated Adviser and Joint Broker)
Freddie Barnfield / Euan Brown / Jack McLaren
Tel: +44 (0) 20 7260 1000
Peel Hunt (Joint Broker)
James Steel / Dr Christopher Golden
Tel: +44 (0) 20 7418 8900
Consilium Strategic Communications - for UK enquiries
Chris Gardner / Matthew Neal
Tel: +44 (0) 20 3709 5700
ergomed@consilium-comms.com (mailto:ergomed@consilium-comms.com)
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END AGMFFFLIRLILFIV